SI1696907T1 - Inhibitorji signaliziranja PDK-1/AKT - Google Patents

Inhibitorji signaliziranja PDK-1/AKT

Info

Publication number
SI1696907T1
SI1696907T1 SI200432057T SI200432057T SI1696907T1 SI 1696907 T1 SI1696907 T1 SI 1696907T1 SI 200432057 T SI200432057 T SI 200432057T SI 200432057 T SI200432057 T SI 200432057T SI 1696907 T1 SI1696907 T1 SI 1696907T1
Authority
SI
Slovenia
Prior art keywords
pdk
akt signaling
signaling inhibitors
inhibitors
akt
Prior art date
Application number
SI200432057T
Other languages
English (en)
Slovenian (sl)
Inventor
Ching-Shih Chen
Original Assignee
The Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34576689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1696907(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Ohio State University Research Foundation filed Critical The Ohio State University Research Foundation
Publication of SI1696907T1 publication Critical patent/SI1696907T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200432057T 2003-10-03 2004-10-04 Inhibitorji signaliziranja PDK-1/AKT SI1696907T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50861903P 2003-10-03 2003-10-03
US50981403P 2003-10-08 2003-10-08
PCT/US2004/032723 WO2005044130A1 (en) 2003-10-03 2004-10-04 Pdk-1/akt signaling inhibitors
EP04816902.3A EP1696907B1 (en) 2003-10-03 2004-10-04 Pdk-1/akt signaling inhibitors

Publications (1)

Publication Number Publication Date
SI1696907T1 true SI1696907T1 (sl) 2013-12-31

Family

ID=34576689

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432057T SI1696907T1 (sl) 2003-10-03 2004-10-04 Inhibitorji signaliziranja PDK-1/AKT

Country Status (9)

Country Link
EP (1) EP1696907B1 (enExample)
JP (1) JP4745971B2 (enExample)
KR (1) KR101217427B1 (enExample)
CN (1) CN1889949B (enExample)
CA (1) CA2566846C (enExample)
DK (1) DK1696907T3 (enExample)
ES (1) ES2420405T3 (enExample)
SI (1) SI1696907T1 (enExample)
WO (1) WO2005044130A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
JP2009519336A (ja) 2005-12-13 2009-05-14 ワイス ジベンゾナフチリジン誘導体およびそれらの使用方法
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20120108823A1 (en) * 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
RU2432112C1 (ru) * 2010-05-27 2011-10-27 Федеральное государственное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "СарНИИТО" Минздравсоцразвития России) Способ прогнозирования послеоперационных осложнений у больных с дегенеративно-дистрофическими поражениями суставов нижних конечностей
DE102010049877A1 (de) * 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
CA2818871A1 (en) * 2010-11-24 2012-05-31 The Ohio State University Research Foundation Integrin-linked kinase inhibitors
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
CN116462606B (zh) * 2022-01-12 2025-11-28 南京宁丹新药技术股份有限公司 一类酰胺衍生化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
KR100263817B1 (ko) * 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5660273A (en) * 1994-07-13 1997-08-26 Centrix, Inc. Single patient dose medicament dispenser with applicator
AU2003230836A1 (en) * 2002-04-08 2003-10-27 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
US7201577B2 (en) * 2002-04-24 2007-04-10 Gosmile, Inc. Tooth whitener applicator and method

Also Published As

Publication number Publication date
EP1696907B1 (en) 2013-04-17
KR101217427B1 (ko) 2013-01-02
WO2005044130A1 (en) 2005-05-19
DK1696907T3 (da) 2013-06-24
CN1889949B (zh) 2010-06-16
EP1696907A1 (en) 2006-09-06
EP1696907A4 (en) 2007-09-05
JP2007527408A (ja) 2007-09-27
ES2420405T3 (es) 2013-08-23
CA2566846C (en) 2012-08-28
CN1889949A (zh) 2007-01-03
JP4745971B2 (ja) 2011-08-10
KR20060108651A (ko) 2006-10-18
CA2566846A1 (en) 2005-05-19
WO2005044130A9 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
TWI369354B (en) Cytokine inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL174010A0 (en) Cytokine inhibitors
ZA200600004B (en) Transcription factors
IL208520A0 (en) Akt protein kinase inhibitors
GB0304515D0 (en) Standard
AU155590S (en) Jar
AU158129S (en) Jar
ZA200707086B (en) Cytokine inhibitors
GB0310841D0 (en) Block
SI1696907T1 (sl) Inhibitorji signaliziranja PDK-1/AKT
GB0322894D0 (en) Telephony system
AU156660S (en) Plate
GB0224861D0 (en) Signalling
GB2407928B (en) Signalling method
GB0318913D0 (en) Apoptosis inhibitors
EP1593416A4 (en) BLOCK
GB0312619D0 (en) Complement inhibitors
GB0329869D0 (en) Inhibitors
GB0300607D0 (en) Inhibitors
GB0300787D0 (en) Telephony signalling
AU155875S (en) Jar
GB0313632D0 (en) Chemokine receptors
GB0327386D0 (en) Complement inhibitors
GB0315324D0 (en) Back-off plate